Senior I
REMIT Consultants, London, England.
Pharmacoeconomics. 1992;1(Suppl 1):70-6. doi: 10.2165/00019053-199200011-00015.
For many years the varying methods of price control of medicines by national governments in the European Community (and elsewhere) have resulted in wide variations in prices. Parallel traders buy products in low pricing Community countries and sell them, generally relabelled or repackaged, in high pricing Community countries. This practice diverts sales revenue and profits from the manufacturers to the traders, distributors, pharmacists and, in some measure, to the sickness funds and to some patients. While parallel trade appeals to those who gain financially, its basis is a market distortion that poses a significant threat to the future of the research-based pharmaceutical industry.
多年来，欧洲共同体（及其他地区）各国政府对药品价格的管控方式各不相同，导致了药品价格的大幅差异。平行进口商在共同体低价国家购买产品，然后通常重新贴标签或重新包装后在共同体高价国家销售。这种做法将销售收入和利润从制造商转移到了贸易商、经销商、药剂师手中，在一定程度上还转移到了疾病基金和一些患者手中。虽然平行进口对那些在经济上获利的人有吸引力，但其基础是市场扭曲，这对以研发为基础的制药行业的未来构成了重大威胁。
